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Abstract: The objective of this work was to investigate the use of nanocrystalline cellulose 
(NCC) as a drug delivery excipient. NCC crystallites, prepared by an acid hydrolysis method, were 
shown to have nanoscopic dimensions and exhibit a high degree of crystallinity. These crystallites 
bound significant quantities of the water soluble, ionizable drugs tetratcycline and doxorubicin, 
which were released rapidly over a 1-day period. Cetyl trimethylammonium bromide (CTAB)   
was bound to the surface of NCC and increased the zeta potential in a concentration-dependent 
manner from −55 to 0 mV . NCC crystallites with CTAB-modified surfaces bound significant 
quantities of the hydrophobic anticancer drugs docetaxel, paclitaxel, and etoposide. These drugs 
were released in a controlled manner over a 2-day period. The NCC-CTAB complexes were 
found to bind to KU-7 cells, and evidence of cellular uptake was observed.
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Introduction
Cellulose has a long history of use in the pharmaceutical industry. The material has 
excellent compaction properties when blended with other pharmaceutical excipients 
so that drug-loaded tablets form dense matrices suitable for the oral administration 
of drugs. The form of cellulose used in tablets is termed microcrystalline cellulose 
(MCC) which is a purified, depolymerized alpha cellulose derived from plant sources.1 
Despite an extended history of use in tableting, there is still considerable c  ontinuing 
research into the use of MCC and other types of cellulose in advanced pelleting 
s  ystems whereby the rate of tablet disintegration and drug release may be controlled 
by microparticle inclusion, excipient layering or tablet coating.2–11
Derivatized cellulose has also been used extensively in pharmaceutical preparations 
so that ethyl cellulose, methyl cellulose, carboxymethyl cellulose, and numerous other 
forms are used in oral, topical, and injectable formulations. For example, c  arboxymethyl 
cellulose is the primary component of Seprafilm™, which is applied to surgical sites 
to prevent post surgical adhesions. Recently, the use of MCC in self-emulsifying drug-
delivery systems and semisolid injectable formulations has also been described.2,12 
The use of these forms of cellulose in such formulations points to the inertness and 
excellent biocompatibility of cellulose in humans. Additionally, hydroxypropyl methyl 
cellulose has recently been used as a hydrogel matrix for chondrocyte implantation 
into animal joints for cartilage repair.13
However, these uses of cellulose in formulations do not involve direct molecular 
level control of drug release via binding interactions with the drug. Although the 
surface of MCC has a slight negative charge due to hydroxyl residues, this charge is International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
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confined to a relatively small surface area on a large mass of 
insoluble MCC and would not likely adsorb or bind significant 
amounts of drug. The principle of using charged particles to 
bind acidic or basic drugs is well established as evidenced by 
the use of ion-exchange resins for the past 50 years to bind 
and release drugs.14 Drug release from resins is usually rapid 
once the resin–drug complex reaches the target site, since 
counter ions present in body fluids displace the drug from the 
binding site. For extended release, resins have been coated 
with agents such as ethyl or carboxymethyl cellulose to delay 
drug elution. Complex polysaccharides such as chitosan have 
been used extensively in controlled release drug f  ormulations. 
Such methods rely on a charge interaction between the 
positive charge on amine groups of each sugar residue in 
chitosan with negatively charged drugs such as antisense 
o  ligonucleotides.15,16 The high positive and negative charges on 
chitosan and oligonucleotides respectively, allow for a strong 
binding interaction between the carrier and the drug so that 
phosphate counterions tend to release a weakly bound fraction 
rapidly and a tightly bound fraction very slowly.16
Nanocrystalline cellulose (NCC) is extracted from 
lignocellulosics by acidic extraction methods resulting in the 
formation of nanodimensional cellulose rods, termed crystal-
lites, with a very high surface to volume ratio.17 Due to its 
large surface area, high aspect ratio, and tremendous stiffness 
and strength, NCC is actively being investigated as a nano-
composite material. For a thorough review of the preparation, 
properties, modification, and application of NCC, readers are 
directed to the excellent review by Habibi et al.18
NCC offers several potential advantages as a drug   delivery 
excipient. The very large surface area and negative charge of 
NCC suggests that large amounts of drugs might be bound 
to the surface of this material with the potential for high 
  payloads and optimal control of dosing. Other nanocrystalline 
m  aterials, such as nanocrystalline clays have been shown to 
bind and subsequently release drugs in a   controlled manner via 
ion exchange mechanisms and are being investigated for use in 
pharmaceutical formulations.19 The established bi  ocompatibility 
of cellulose supports the use of NCC for a similar purpose. 
The abundant surface hydroxyl groups on NCC provide a site 
for the surface modification of the m  aterial with a range of 
chemical groups by a variety of methods. Surface modifica-
tion may be used to modulate the loading and release of drugs 
that would not normally bind to NCC, such as nonionized or 
hydrophobic drugs. For example, Lonnberg et al suggested that 
poly(caprolactone) chains might be conjugated onto nanocrys-
talline cellulose for such a purpose.20 Additionally, since NCC 
is a low-cost, readily abundant material from a renewable and 
s  ustainable resource, its use provides a substantial e  nvironmental 
  advantage c  ompared with other nanomaterials.
The objectives of this work were to investigate the   binding 
and release of a range of ionized drugs from NCC and to 
surface modify NCC with the surfactant, cetyl trimethylam-
monium bromide (CTAB) for the binding and release of 
hydrophobic drugs. To our knowledge, this is the first report 
of the use of NCC as a drug delivery excipient.
Materials and methods
Materials
Nanocrystalline cellulose was prepared according to the 
method outlined below by FPInnovations (Vancouver, BC, 
Canada). A 4 mg/mL suspension in deionized water was 
used for this investigation. Docetaxel was obtained from 
Natural Pharma Inc, (Vancouver, BC, Canada).   Doxorubicin 
hydrochloride, paclitaxel, and etoposide were supplied by 
Polymed Therapeutics, Inc (Houston, TX, USA). Cetyl 
trimethylammonium bromide and tetracycline hydrochloride 
were supplied by Sigma Aldrich (Oakville, ON, Canada). 
Methoxy poly(ethylene glycol)-block-poly (D,L lactide) 
(MePEG-b-PDLLA) diblock copolymer was synthesized 
and characterized as previously described.21
Ncc preparation
NCC was prepared by a previously reported method.22 Briefly, 
a fully bleached, commercial softwood was milled to pass 
through a 0.5-mm screen in a Wiley mill to ensure particle 
size uniformity and increased surface area. The milled pulp 
(40.0 g) was hydrolyzed in 64% w/w sulfuric acid (8.75 mL of 
a sulfuric acid solution/g pulp) at 45°C and stirred at high speed 
for 25 minutes. The cellulose suspension was then diluted with 
cold, deionized distilled water (dH2O) and allowed to settle 
overnight. The clear top layer was decanted and the remain-
ing white cloudy layer was washed with d  eionized water 
and c  entrifuged three times to remove   practically all soluble 
cellulose materials. The resulting thick, white suspension 
was dialyzed against slow running dH2O for 1–4 days using 
dialysis tubing with a 12,000–14,000   molecular weight 
cutoff (Spectra/Por®, Spectrum Laboratories, Inc, Rancho 
Dominguez, CA, USA). The suspension from the dialysis 
tubes was dispersed by subjecting it to ultrasound treatment 
in a Fisher Sonic Dismembrator (Fisher Scientific, Ottawa, 
ON, Canada) for 10 minutes at 60% power.
X-ray powder diffraction
Diffraction data were collected on films of lyophilized 
and air dried NCC using a previously described method.23 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Briefly, a Bruker D8 Advance powder x-ray diffractometer 
(Bruker Corporation, Milton, ON, Canada) equipped with a 
CuXα x-ray tube, a diffracted beam graphite monochromator, 
and Nal scintillation detector was used with the generator 
set to 40 kV and 40 mA. Data was collected from 5°–90° 
2θ using a step size of 0.02° and a counting time of 1 sec/step. 
A   divergence of 1.00 mm and anti-scatter slits were used with 
a 0.2 mm receiving slit, and the sample was rotated during 
data collection. The films were mounted on zero-background 
Si plates. The peaks were assigned according to the mono-
clinic unit cell for cellulose I. The crystallinity was obtained 
from the x-ray intensity, as described by Hamad and Hu.23
Imaging
Air-dried films or a drop of the NCC suspension in dH2O 
were mounted on aluminum stubs using adhesive carbon tabs, 
and the stubs were sputter-coated with AuPd. Morphological 
characteristics were observed using an FEI Quanta 400F 
field-emission scanning electron microscope (SEM) (FEI 
Company, Hillsboro, OR, USA), operated in high vacuum 
mode with a 5 kV accelerating voltage.
Ncc drug binding
Doxorubicin  hydrochloride  (DOX)  or  tetracycline 
h  ydrochloride (TET) were dissolved in either 10 mM p  hosphate 
buffered saline (PBS) at pH 7.4, or dH2O with increasing drug 
concentrations ([drugadded]). Drug s  olutions (1.5 mL) were 
added to 0.5 mL of a 4 mg/mL NCC suspension (2 mg of 
NCC) in a 2 mL microcentrifuge tube and incubated at 37°C 
with tumbling at 8 rpm for 30 minutes. Suspensions contain-
ing PBS or NaCl produced flocculated NCC/drug suspen-
sions, which were centrifuged at 18000 × g for 10   minutes 
to pellet the NCC and bound drug. The c  oncentration of 
unbound drug in the supernatant ([drugunbound]) was assayed 
using a Varian 50 Bio UV Vis spectrophotometer (Varian, 
Inc., Mississauga, ON, Canada) using wavelengths of 482 nm 
and 364 nm for DOX and TET, respectively. The concentra-
tion of drug bound to the NCC ([drugbound]) was calculated 
using the following formula:
  [drugbound] = [drugadded] – [drugunbound].  (1)
NCC does not flocculate in dH2O; therefore, the NCC/drug 
complexes prepared in dH2O could not be separated by 
microcentrifugation. In this case, the NCC/drug suspensions 
were transferred to dialysis bags with a molecular weight 
cutoff of 10,000 Da (Spectra/Por®, Spectrum Laboratories, 
Inc., Rancho Dominguez, CA, USA) and dialyzed against 
dH2O overnight in the dark at 4°C. The concentration of 
unbound drug in the dialysate was determined by UV Vis 
spectroscopy, allowing for the calculation of the amount of 
drug bound to the NCC according to Equation 1.
To solubilize the hydrophobic drugs paclitaxel (PTX), 
docetaxel (DTX), and etoposide (ETOP), the surface of the 
NCC was first modified with CTAB. This was achieved by 
incubating increasing amounts of CTAB with 2.5 mg of 
NCC so the final CTAB concentration varied from 0 mM 
to 12.9 mM. An aliquot of 100 mM NaCl was added, 
resulting in a final NaCl concentration of 10 mM, which 
facilitated fl  occulation and subsequent separation of the 
NCC/CTAB nanocomplexes by centrifugation as described 
above. The NCC/CTAB was incubated with stock solutions 
of the drugs with increasing concentrations. Since these 
drugs are c  haracterized by low aqueous solubility, they 
were solubilized in a minimal amount of either DMSO or 
MePEG-b-PDLLA diblock copolymer in 10 mM NaCl as 
previously described.21 The drug/NCC/CTAB suspensions 
were in  cubated at 25°C with tumbling at 8 rpm for 30 minutes 
then centrifuged at 18000 × g for 10 minutes to pellet the 
NCC/CTAB and bound drug. The amount of unbound drug 
in the supernatant was determined by high performance 
liquid chromatography (HPLC) using a Waters HPLC system 
with Millennium software and UV Vis detection (Waters 
Ltd, Mississauga, ON, Canada). Separation was achieved 
using a Novapak C18 column with 20 µL injections and 
a mobile phase flow rate of 1 mL/min. The DTX and PTX 
mobile phase consisted of 58% acetonitrile, 37% dH2O, and 
5% methanol, with detection at 232 nm. The mobile phase 
for ETOP was 27% acetonitrile, 1% acetic acid, and 72% 
dH2O, and detection was at 286 nm. Calibration curves were 
prepared for all drugs and were linear in the desired concen-
tration range. The amount of drug bound to the NCC/CTAB 
was determined using Equation 1.
Drug release studies
DOX was bound to NCC for release studies by incubating a 
solution of 325 µg/mL of DOX in dH2O with a s  uspension 
containing 2.5 mg of NCC. To flocculate the NCC and allow 
for separation of the NCC/DOX nanocomplex, NaCl was 
added to a final concentration of 10 mM. The suspension was 
centrifuged at 18000 × g for 10 minutes to pellet the NCC/
DOX, and the drug binding was determined by UV Vis spec-
troscopy as described above. The final mass of DOX bound to 
the NCC for the release studies was 212 ± 3.5 µg. The same 
procedure was used to prepare TET-bound NCC nanocom-
plexes for the release studies, with the exception that the initial 
TET solution used was 1000 µg/mL, which resulted in the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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binding of 187 ± 2.0 µg of TET. NCC/drug nanocomplexes 
with DTX, PTX, and ETOP were prepared as described for 
the drug-binding studies. The c  oncentration of DTX and PTX 
that was incubated with the NCC suspension was 200 µg/mL, 
and the concentration of ETOP was 100 µg/mL. The final mass 
of drug bound to the NCC was 184 ± 4.8 µg, 149 ± 4.8 µg, 
and 63 ± 0.1 µg for DTX, PTX, and ETOP, respectively. The 
drug loaded NCC samples were resuspended in 1 mL of 
PBS followed by incubation at 37°C with tumbling at 8 rpm. 
At predetermined times, the suspensions were centrifuged at 
18000 × g for 10 minutes, and the supernatant was removed 
for drug quantification by UV Vis for DOX and TET or HPLC 
for DTX, PTX, and ETOP, as previously described. At each 
sampling time point, fresh PBS was added to the tubes, and 
the NCC/drug nanocomplexes were resuspended.
Zeta potential measurements
The effect of CTAB concentration on zeta potential of NCC 
was determined by incubating 2.5 mg samples of NCC with 
increasing concentrations of CTAB in dH2O to yield final 
CTAB concentrations of 0, 0.755, 1.13, 1.51, 1.89, 2.27, and 
3.02 mM. The zeta potentials of the samples were measured 
using a Malvern 3000 HS-Zetasizer (Malvern Instruments 
Ltd, Malvern, UK).
cell binding and uptake studies
KU-7 bladder cancer cells were a kind gift from Dr Martin 
Gleave at the Prostate Centre, Vancouver General Hospital 
and were grown in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% fetal bovine serum, 5% glutamine, 
and 5% penicillin/streptomycin. Cells were plated at 
10,000 cells per well on a 96-well cell culture plate and 
allowed to equilibrate overnight. NCC for binding studies 
was prepared by coating with CTAB followed by fluorescein 
binding. Briefly, 2 mg of NCC were suspended in a 3 mM 
CTAB in 5 mM sodium chloride solution for 30 minutes 
at 37°C. The suspension was centrifuged at 18,000 × g for 
30 seconds and the supernatant discarded. The pellet was 
resuspended in 1 mL of a 5 mM sodium chloride solution con-
taining 100 µg/mL fluorescein and incubated for 30 minutes 
at 37°C. The suspension was centrifuged at 18,000 × g for 
30 seconds, and the supernatant was discarded followed by 
resuspension in PBS and serial dilution to give concentrations 
ranging from 10 to 0.06 mg/mL. To each cell culture plate 
well, 200 µL of each NCC suspension was added, and the 
cells were allowed to incubate for 24 hours. The media was 
removed and the cells washed three times with PBS prior to 
lysis with 2% Triton X-100. The fluorescence intensity of the 
NCC/CTAB/fluorescein bound to the cells was determined 
using a fluorescence spectroscopy plate reader with excitation 
and emission wavelengths of 480 and 520 nm,   respectively. 
These values were converted to mass of NCC/CTAB/
fl  uorescein bound to cells using a previously constructed 
standard curve of fluorescence intensity as a function of mass 
of NCC/CTAB/fluorescein. A BCA total protein assay kit 
(Pierce Chemicals, Rockford, IL, USA) was used to ensure 
that each well contained the same number of cells.
To visualize cell uptake of NCC, KU-7 cells were 
cultured as described for the binding studies. Glass cover 
slips (1 cm diameter) were sterilized and placed in the 
base of 6 well   tissue culture plates followed by the addi-
tion of 50,000 cells to each well and incubation overnight. 
Cells were incubated with a 1.25 mg/mL NCC/CTAB/
fluorescein suspension for various times at 37°C under 
culture c  onditions. The cover slips were removed, washed 
three times in PBS and then treated with 4′,6-  diamidino-2-
phenylindole (DAPI) in Progold stain for 30 minutes, washed 
again and then treated with 3.7% p  araformaldehyde in dH2O 
for 30 minutes. The cover slips were placed cell side down 
on microscope slides and sealed with clear nail varnish. 
Fluorescein- and DAPI-stained nuclei were v  isualized using 
an Olympus FV-1000 confocal laser scanning microscope 
(Olympus Canada, Inc., Markham, ON, Canada).
Results
X-ray powder diffraction  
and imaging of Ncc
The X-ray powder diffraction (XRPD) pattern of NCC was 
characterized by two major peaks centered around 15° and 
23° 2θ (Figure 1). The degree of crystallinity of the sample 
was calculated to be greater than 90%. The SEM images 
of NCC as a dried film show a layered pattern of NCC 
c  rystallites oriented in a common direction (Figure 2A). 
Figure 1 X-ray powder diffraction pattern of lyophilized nanocrystalline cellulose. 
Intense peaks at 15° and 23° 2θ, due to constructive interference of diffracted 
x-rays, in addition to the lack of an amorphous halo, indicate the highly crystalline 
nature of the material.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The scanning transmission electron microscopy (STEM) 
m  icrograph of the NCC suspension shows individual NCC 
fibers with approximate dimensions of 10 nm wide by 500 nm 
in length (Figure 2B).
Drug binding to Ncc
The amount of DOX bound to NCC increased significantly 
as the mass of drug added to the NCC suspension increased. 
When the dispersion medium was PBS, a maximum of 
122 µg of DOX was bound to NCC representing a 65% 
binding efficiency (Figure 3A). When dH2O was used as 
the dispersion medium, a maximum of 1667 µg of DOX 
was bound to NCC with a binding efficiency of 83% 
(  Figure 3B). It was found that the binding efficiency of TET 
to NCC was   considerably less than that of DOX, re  gardless 
of the dispersion medium used (Figure 4). Using PBS 
as a dispersion medium, a maximum of 251 µg of TET was 
bound with a 25% binding efficiency (Figure 4A). When the 
dispersion medium was dH2O, 959 µg of TET was bound to 
NCC with a 48% b  inding efficiency (Figure 4B).
The effect of increasing concentration of CTAB coating 
on NCC on the binding of the hydrophobic drugs DTX, PTX, 
and ETOP was investigated (Figures 5–7). In all cases it was 
found that increased amounts of CTAB resulted in increased 
drug binding. At the highest CTAB concentration (12.9 mM), 
the binding efficiency of DTX and PTX to the NCC/CTAB 
nanocomplexes was approximately 90% up to 100 µg of drug 
added (Figures 5A and 6A). Above this drug c  oncentration, 
the drug-binding efficiency decreased with saturation of 
b  inding occurring at approximately 200 µg (Figure 5B 
and 6B). Much less ETOP was capable of b  inding to the 
NCC/CTAB nanocomplexes with a 48% binding efficiency 
and a maximum of 48 µg bound when 100 µg of drug was 
added to the NCC/CTAB (Figure 7).
0
50
100
150 A
B
05 01 00 1502 00
Mass of doxorubicin added (µg)
M
a
s
s
 
o
f
 
d
o
x
o
r
u
b
i
c
i
n
 
b
o
u
n
d
 
t
o
 
N
C
C
 
(
µ
g
)
Mass of doxorubicin added (µg)
M
a
s
s
 
o
f
 
d
o
x
o
r
u
b
i
c
i
n
 
b
o
u
n
d
 
t
o
 
N
C
C
 
(
µ
g
)
0
500
1000
1500
2000
0 500 10001 5002 0002 500
Figure 3 The binding of doxorubicin to 2 mg Ncc in 10 mM, ph 7.4 phosphate 
buffered saline at 25°c (A) and deionized distilled water at 25°c (B). 
Abbreviation: Ncc, nanocrystalline cellulose.
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Figure 2 Scanning electron micrograph of a dried film of nanocrystalline cellulose 
(Ncc) (A) and Ncc crystallites in deionized distilled water (B).
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release of drugs from Ncc
Both DOX and TET released rapidly from NCC,   resulting in 
approximately 90% of bound TET and 85% of bound DOX 
released in 4 hours (Figure 8). By day 1, the drug release had 
plateaued, with 93% and 87% of TET and DOX released, 
respectively. The release profiles of the hydrophobic drugs 
DTX, PTX, and ETOP bound to NCC/CTAB are shown in 
Figure 9. Approximately 26% of DTX was released within 
the first hour, followed by a slower but sustained release. In 
total, 59% of the total bound DTX was released in 2 days. 
A similar release profile was observed for PTX, which was 
characterized by a rapid release of 20% of bound drug in the 
first hour followed by slower release resulting in 44% drug 
release over 2 days. The release of ETOP was similar to DTX 
and PTX, with the exception that a total of 75% of the drug 
was released over 4 days.
Ncc/cTAB characterization
In dH2O, NCC remained as a stable colloidal d  ispersion 
and did not flocculate or sediment under high-speed 
c  entrifugation. However, when 5 mM of NaCl was added, 
flocculation and subsequent sedimentation by high-speed 
centrifugation could be achieved. In water, CTAB had the 
same effect as NaCl so that at approximately 2 mM CTAB, 
the NCC could be sedimented under centrifugation. At lower 
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Figure 5 A) The binding of docetaxel to 2.5 mg of Ncc/cTAB nanocomplexes 
in  10  mM  Nacl  at  25°c  with  cTAB  concentrations  of  0  mM  (),  0.755  mM 
(▲), 1.51 mM (▼), 2.27 mM (♦), 4.53 mM (), 6.79 mM (), and 12.9 mM (∆). 
B) Maximal binding of docetaxel at a cTAB concentration of 12.9 mM. 
Abbreviations: cTAB, cetyl trimethylammonium bromide; Ncc, nanocrystalline 
cellulose.
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Figure 6 A) The binding of paclitaxel to 2.5 mg of Ncc/cTAB nanocomplexes 
in 10 mM Nacl at 25°c with cTAB concentrations of 0 mM (), 0.755 mM (▲), 
1.51 mM (▼), 2.27 mM (♦), 4.53 mM (), 6.79 mM (), and 12.9 mM (∆). B) Maximal 
binding of paclitaxel at a cTAB concentration of 12.9 mM. 
Abbreviations: cTAB, cetyl trimethylammonium bromide; Ncc, nanocrystalline 
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Figure 7 The binding of etoposide to 2.5 mg of Ncc/cTAB nanocomplexes in 
10 mM Nacl at 25°c with cTAB concentrations of 0 mM (), 0.375 mM (▲), 
0.755  mM  (▼),  1.51  mM  (♦),  2.27  mM  (),  4.53  mM  (),  and  6.79  mM  (∆), 
and 12.9 (∇). 
Abbreviations: cTAB, cetyl trimethylammonium bromide; Ncc, nanocrystalline 
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concentrations of CTAB, a small amount of NaCl (10 mM) 
was added to tubes to enable sedimentation.
NCC had a strongly negative charge in water as evi-
denced by a zeta potential of approximately −55 mV . Upon 
incubation with CTAB, the zeta potential increased in a 
concentration-dependent manner. At a concentration of 
3 mM CTAB, there was complete neutralization of the nega-
tive zeta potential (Figure 10).
cell binding and uptake studies
More than 95% of the fluorescein bound to NCC/CTAB 
remained bound upon resuspension or dilution in aqueous 
media. When NCC/CTAB/fluorescein was incubated with 
KU-7 cells, the fluorescence signal was not quantifiable 
below 0.3 mg/mL; however, above this concentration, the 
fluorescence increased in a concentration-dependent m  anner 
(Figure 11). At NCC/CTAB/fluorescein c  oncentrations 
greater than 1.25 mg/mL, there was no linearity of the 
  fluorescein quantitation, and it was not possible to accurately 
measure fluorescein uptake or binding to the cells.
The nuclei of the KU-7 cells displayed pronounced 
staining with DAPI as shown in Figure 12B. There is clear 
evidence of cellular uptake of fluorescein as demonstrated by 
strong fluorescence emission from the cytoplasm of the cells 
(Figure 12C). The uptake of fluorescein reached a maximum 
by 2 hours with little increase in cytoplasmic fluorescence 
emission after longer incubations. Cell uptake was observed 
using NCC/CTAB/fluorescein nanocomplex concentrations 
of 0.25, 0.50, and 1.00 mg/mL. There was no evidence of 
cell lysis with these complexes for up to 24 hours.
Discussion
Due its large surface area, stiffness, strength, and phase 
behavior, NCC is actively being investigated as a   material 
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Figure  8  The  in  vitro  release  of  doxorubicin  (∆)  and  tetracycline  ()  from 
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Figure 10 Zeta potential of Ncc/cTAB nanocomplexes as a function of cTAB 
concentration. 
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for use in the packaging, aerospace, automotive, and 
c  osmetic industries. However, to our knowledge, this is 
the first report of the use of NCC as an excipient for drug 
binding and s  ubsequent controlled release. The high sur-
face charge of NCC and the established biocompatibility 
of cellulosic materials suggest significant opportunities for 
exploration of the potential pharmaceutical applications of 
NCC. Other workers have described the use of chitosan, a 
positively charged insoluble polysaccharide, as a binding 
agent for the controlled release of negatively charged anti-
sense oligonucleotide (ASO) drugs.15,16 In such studies, the 
chitosan/ASO complexes were used either alone or dispersed 
in a polymeric vehicle for the treatment of cancer.
Using an acid hydrolysis method, cellulose c  rystallites, 
or what we termed NCC crystallites, were isolated and 
i  nvestigated for use as a drug delivery excipient. The XRPD 
pattern, which is characterized by two high i  ntensity peaks, 
indicates the high degree of crystallinity of the material 
(  Figure 1). Additionally, the SEM images of these fibers 
clearly demonstrate the nanoscopic dimensions of this 
m  aterial when in a dH2O suspension (Figure 2B) and, 
as reviewed by Hamad,17 the ability of the material to yield 
a chiral nematic phase when dried as a film (Figure 2A).
These studies have demonstrated that hydrophilic drugs 
may bind directly to the surface of NCC at relatively high 
weight ratios (Figures 3 and 4) (eg, almost 500 µg of TET 
may be bound to just 2 mg of NCC, offering a 20% w/w 
drug loading (Figure 4)). The two hydrophilic drugs studied 
(TET and DOX) probably bound by an ionic interaction 
with the negatively charged surface of NCC since DOX is 
a cationic species slightly positively charged and TET is 
zwitterionic. Interestingly, considerably less DOX bound to 
NCC when dispersed in PBS as compared with dH2O. This 
may be attributed to interference with DOX binding due to 
the presence of large amounts of counterions in PBS. Both 
these agents released rapidly from NCC in vitro (Figure 8), 
likely due to PBS counterions displacing the drugs via ion 
exchange. Such rapid release profiles are also seen for acidic 
or basic drugs bound to ion-exchange resins.14 Nevertheless, 
these rapid-release profiles observed for NCC may be   suitable 
for potential applications as wound-dressing materials or 
for implantation into surgical resection voids such as tumor 
removal sites or periodontal cavities.
This work also demonstrates that NCC can be surface 
modified to deliver hydrophobic antiproliferative drugs. 
By coating the negatively charged NCC with a cationic 
surfactant (CTAB) it was possible to create a hydrophobic 
domain on the surface of the NCC. A clear interaction 
between CTAB and NCC was observed by flocculation 
phenomena at higher CTAB concentrations. Furthermore, 
the zeta p  otential (s  urface charge) on the NCC became 
increasingly less negative as the concentration of CTAB 
increased, providing evidence of a binding interaction 
between the CTAB and the NCC (Figure 10). The strong 
association between NCC and CTAB was further supported 
by washing experiments whereby flocculation phenomena 
only began to decay when the NCC/CTAB nanocomplexes 
were washed more than 15 times with PBS (data not shown). 
Other groups have observed a similar interaction between 
CTAB and negatively charged gold nanoparticles whereby 
the surfactant binds to the surface of the particle and may 
cause concentration dependent particle aggregation.24 
Furthermore, Alkilany et al25 described the partitioning 
of hydrophobic napthol molecules into surfactant-coated 
gold nanorods. I  nterestingly, although gold nanoparticles 
are used for laser-induced thermal ablation of tumors, 
these particles have also been modified with hydrophobic 
polymer chains for the purpose of delivering hydrophobic 
drugs in a manner similar to CTAB use on NCC described 
in this study.26
The hydrophobic drugs DTX, PTX, and ETOP par-
titioned strongly into the CTAB domains on NCC using 
either free drug solutions at low concentrations or micellar 
solubilized drugs at higher concentrations (Figures 6 and 7). 
A B
C D
Figure  12  confocal  micrographs  of  KU-7  cells  incubated  for  2  hours  with 
NCC/CTAB/fluorescein nanocomplexes with a NCC/CTAB/fluorescein concentration 
of 0.25 mg/mL. A) White light image of KU-7 cells. B) staining of the nuclei with DAPI. 
C) Fluorescein in the cytoplasm. D) An overlay of images B and c. 
Abbreviations: cTAB, cetyl trimethylammonium bromide; DAPI, 4’,6-diamidino-
2-phenylindole; Ncc, nanocrystalline cellulose.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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These drugs released more slowly from NCC (Figure 9) than 
the h  ydrophilic drugs DOX and TET. However, the release 
profiles were all characterized by a burst phase of release of 
between 40% and 75% of the bound drug over the first 2 days 
followed by an extremely slow rate of release. These profiles 
suggest a weakly bound fraction of drug releasing quickly 
and a strongly bound fraction that released very slowly.
These NCC/CTAB nanocomplexes were shown to asso-
ciate strongly with KU-7 cancer cells (Figure 11). Because 
fluorescein was strongly bound within the CTAB coating on 
the NCC, it was possible to quantitate the cell-bound NCC 
by measuring the fluorescein emission from the cells. This 
assay does not differentiate between cell surface association 
and cellular uptake of NCC but clearly shows that NCC 
may be used to carry agents (in this case a hydrophobic 
probe, fluorescein) to cells. This concept is supported by 
confocal microscopy studies showing a strong fluorescence 
signal from the cytoplasm of the cancer cells (Figure 12). 
In these studies, the nuclear and cytoplasmic regions 
were di  fferentially stained with DAPI (Figure 12B) and 
fluorescein (Figure 12C), respectively. No fluorescein signal 
was observed in the location of the nucleus, suggesting the 
cytoplasm as the location of fluorescein, since surface-bound 
fluorescein would be observed over the full exposure of the 
cells. These data indicate cellular uptake of fluorescein but 
do not differentiate the uptake of free fluorescein from the 
NCC/CTAB/fluorescein nanocomplexes, as it is possible 
that fluorescein may partition into the hydrophobic cell 
membrane following cell binding of the nanocomplexes. 
Since cellular uptake of fluorescein was almost complete by 
2 hours and anticancer drugs such as ETOP, PTX, and DTX 
release occurred over days (Figure 9), it may be assumed 
that NCC/CTAB/drug nanocomplexes offer a viable and 
novel method of delivering drugs to cells and may actually 
deliver these anticancer drugs as controlled release systems 
(NCC/CTAB/drug nanocomplexes) within cells. These 
confocal studies also indicate the biocompatibility of the 
NCC/CTAB/nanocomplexes, since cells were intact fol-
lowing incubation with the nanocomplexes for 24 hours. In 
cytotoxicity studies measuring the release of lactate dehydro-
genase (a marker of cytolysis), NCC and NCC-CTAB were 
found to have no lytic effect at a concentration of 1 mg/mL 
(data not shown). However, upon dilution in PBS, lower 
  concentrations of NCC/CTAB (not NCC) were observed 
to cause some background lysis, indicating that some 
unbound CTAB might interact directly with the cancer cell 
membranes. The potential cytotoxic effect of CTAB bound 
to NCC is under further investigation.
Conclusion
In these studies, we investigated the potential of NCC as a 
drug delivery excipient. It was demonstrated that NCC was 
capable of binding significant quantities of the i  onizable 
water soluble a  ntibiotics tetracycline and d  oxorubicin. 
These hydrophilic drugs were rapidly released with com-
plete release in 1 day. It was shown that the surface of 
NCC could be modified by b  inding the cationic surfactant 
CTAB, r  esulting in a c  oncentration dependent increase in the 
zeta potential of the NCC crystallites. CTAB-coated NCC 
was shown to bind significant quantities of the nonionized 
h  ydrophobic a  nticancer agents docetaxel, paclitaxel, and 
etoposide and release these drugs in a controlled manner 
over several days. The NCC/CTAB nanocomplexes bound 
to KU-7 bladder cancer cells and demonstrated efficient 
delivery of a hydrophobic fluorescent probe fluoroscein 
to the cytoplasm of these cells. Overall, these studies have 
established the potential of NCC as a drug delivery e  xcipient 
for use alone or in conjunction with other formulations.
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